Editorial Comment: The Prostate Cancer Prevention Trial (PCPT) identified a 25% decrease
in the risk of prostate cancer following 7 years of finasteride treatment. Since the study was …

Purpose: Prostate cancer is the most common male cancer, affecting one man in six.
Prevention of this disease, even in a subset of patients would have a significant impact on …

OBJECTIVES: Finasteride reduced the risk of prostate cancer by 24.8% in the Prostate
Cancer Prevention Trial (PCPT). Whether this represents treatment or prevention and who is …

This study linked Medicare claims and National Death Index data to clinical trial records from
the Prostate Cancer Prevention Trial to characterize the long-term implications of finasteride …

Background: Finasteride has been found to reduce the risk of low-grade prostate cancer but
to have no impact on overall survival. The long-term adverse and beneficial consequences …

Background Investigators have used administrative claims to better understand cancer
outcomes when a research question cannot feasibly be examined within a study. The …

Background: Little is known about how physicians assimilate evidence regarding prostate
cancer prevention. Finasteride, a drug studied as a chemopreventive agent for prostate …

The PCPT demonstrated that 7 years of prophylactic treatment with finasteride reduced the
risk of prostate cancer by 6%(from 24.4% in the placebo group to 18.4% in the finasteride …

Opinion statement Prostate cancer is an important public health problem. Chemoprevention
offers an attractive solution because it may lead to decreased disease-specific mortality …

Purpose Finasteride has been shown to reduce the incidence of prostate cancer. Yet the use
of finasteride remains low, likely because of the risk of adverse effects. We sought to …